Cardiff Oncology CRDF Insider Ownership

NASDAQ CRDF

$0.95 +0.02 (+1.62%)

As of: Oct 22, 2026 · 12:44 PM EDT

Insider Holdings by Owner

2.34Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

5.47%

▲+1.05% pp QoQ

Shares Held by Insiders

3.75Mn

filed for Sep 2026

▲+23.85% QoQ

Shares Outstanding

68.50Mn

68,502,000 shares

Direct Holdings

2.21Mn

Indirect: 1.54Mn

Net Shares Traded (QoQ)

+721.65K

net buying in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the trailing 12 months, CRDF insiders bought $1.12 million worth of shares (776.35K shares) in open-market trades, with no open-market sales.

By number of insiders, Cardiff Oncology saw 2 insiders buy on the open market over the past 12 months and none sell.
Among CRDF insiders, Gary W. Pace (Director) bought the most stock on the open market in the past 12 months: $1.04 million (717.28K shares), most recently on July 14, 2026.
Per Business Quant data, Cardiff Oncology insiders hold 3.75Mn shares in total based on their latest Form 4 filings, up 23.85% from 3.03Mn shares at the end of Q2 2026 and up 24.05% from 3.02Mn shares at the end of Q3 2025.
Direct holdings account for 2.21Mn shares (58.90%) of CRDF's insider total, and indirect holdings through trusts, partnerships and family members for 1.54Mn shares (41.10%).
Holdings in Cardiff Oncology stock are reported by 7 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
Cardiff Oncology's three biggest insider holders are Gary W. Pace (Director, 3.39Mn shares), James E. Levine (Chief Financial Officer, 127.72K shares) and Lale White (Director, 113.79K shares), based on their latest Form 4 filings.
The holding of Gary W. Pace makes up 90.45% of all shares held by Cardiff Oncology insiders.
Institutional investors held 27.38% of Cardiff Oncology stock at the end of Q2 2026, while the latest Form 4 filings of its insiders account for about 5.47%; other investors, including the public, hold roughly 67.15%.
A total of 16 Form 4 filings with transactions in Cardiff Oncology stock were made over the past 12 months, by 10 insiders.
These insider figures for Cardiff Oncology are based on Form 4 filings through July 16, 2026.

Form 4 Holdings

Insiders Holding CRDF

Insiders 7

Shares held 2.34Mn

Of outstanding 3.42%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Gary W Pace	Director	2,043,661	0	2,043,661	87.3%	16 Jul, 2026
2	Lale White	Director	0	113,788	113,788	4.9%	20 Sep, 2022
3	James E. Levine	Chief Financial Officer	0	67,716	67,716	2.9%	18 Dec, 2024
4	Mani Mohindru	Chief Executive Officer	59,067	0	59,067	2.5%	16 Jul, 2026
5	Mark Erlander	Chief Executive Officer	24,481	0	24,481	1.0%	29 Nov, 2022
6	Renee P Tannenbaum	Director	20,000	0	20,000	0.9%	16 Dec, 2024
7	James O Armitage	Director	0	13,000	13,000	0.6%	11 Oct, 2022

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

374 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
14 Jul, 2026	Mani Mohindru	Chief Executive Officer	Acquired P	34,364	$1.46	$50.00K	59,067	Direct
14 Jul, 2026	Gary W Pace	Director	Acquired P	687,285	$1.46	$1,000.00K	2,043,661	Direct
14 Jul, 2026	Gary W Pace	Director	Acquired P	687,285	$0.00	$0	687,285	Direct
14 Jul, 2026	Mani Mohindru	Chief Executive Officer	Acquired P	34,364	$0.00	$0	34,364	Direct
18 Jun, 2026	Gary W Pace	Director	Acquired P	30,000	$1.22	$36.60K	1,356,376	Direct
18 Jun, 2026	Mani Mohindru	Chief Executive Officer	Acquired P	24,703	$1.21	$29.89K	24,703	Direct
11 Jun, 2026	Gary W Pace	Director	Acquired A	40,565	$0.00	$0	228,104	Direct
11 Jun, 2026	Renee P Tannenbaum	Director	Acquired A	40,565	$0.00	$0	209,331	Direct
11 Jun, 2026	James O Armitage	Director	Acquired A	40,565	$0.00	$0	228,104	Direct
11 Jun, 2026	Lale White	Director	Acquired A	40,565	$0.00	$0	199,246	Direct
11 Jun, 2026	Rodney S Markin	Director	Acquired A	40,565	$0.00	$0	263,430	Direct
27 Apr, 2026	Ajay Aggarwal	Chief Operating Officer	Acquired A	400,000	$0.00	$0	400,000	Direct
14 Apr, 2026	Tod Smeal	Chief Scientific Officer	Acquired A	300,000	$0.00	$0	1,279,805	Direct
06 Apr, 2026	Joshua B Muntner	Chief Financial Officer	Acquired A	486,650	$0.00	$0	487,150	Direct
06 Apr, 2026	Joshua B Muntner	Chief Financial Officer	Acquired A	486,650	$0.00	$0	487,150	Direct
31 Mar, 2026	Mani Mohindru	Chief Executive Officer	Acquired A	600,000	$0.00	$0	968,766	Direct
13 Feb, 2026	Brigitte Ute Lindsay	Chief Accounting Officer	Acquired A	200,000	$0.00	$0	1,025,334	Direct
17 Feb, 2026	Mani Mohindru	Interim Ceo	Acquired A	200,000	$0.00	$0	368,766	Direct
30 Jul, 2025	Gary W Pace	Director	Acquired P	275,000	$2.45	$673.75K	1,330,676	Direct
30 Jul, 2025	Gary W Pace	Director	Acquired P	15,000	$2.45	$36.75K	1,345,676	Indirect

Showing 1 to 20 of 374 transactions